MetaCap

Dare Bioscience (DARE) vs Vistagen Therapeutics (VTGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dare Bioscience (DARE) has outperformed Vistagen Therapeutics (VTGN) over the past year, losing 75.8% versus a loss of 96.4%. Over five years, DARE leads with a -98.1% price change compared with -99.7% for VTGN. Dare Bioscience is the larger company by market cap ($8.0 million vs $7.6 million), about 1.1 times the size.

Dare Bioscience converts more of its revenue into profit, with a net margin of -1300.7% versus -5491.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DARE-75.75%VTGN-96.44%
+104%-1%-106%
Nov 21, 20251 yearNov 20, 2026
DARE-97.97%VTGN-99.75%
+30%-38%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DARE versus VTGN key metrics
MetricDAREVTGN
Share price$0.4074$0.1636
Market cap$8.01M$7.56M
1-day change-9.87%-12.33%
YTD return-78.89%-75.21%
1-year return-75.75%-96.44%
5-year return-98.10%-99.72%
EPS (TTM)$-0.61$-1.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.03M$1.27M
Revenue growth (YoY)+10429.36%+161.11%
Net income (latest FY)$-13.40M$-69.69M
Gross margin71.29%—
Operating margin-1315.51%-5683.69%
Net margin-1300.66%-5491.33%
52-week high$3.78$5.14
52-week low$0.406$0.16
Distance from 52-week high-89.22%-96.82%
Analyst consensusnonenone
Avg. price target upside+1944.67%+511.25%
Average volume242.39K10.30M
Shares outstanding19.67M46.19M
Employees2141
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DARE has outperformed VTGN by 20.7 percentage points over the past year.
  • Dare Bioscience is more profitable, keeping -1300.7 cents of every revenue dollar as net income versus -5491.3 cents for Vistagen Therapeutics.
  • Dare Bioscience grew revenue faster in its latest fiscal year (+10429.36% vs +161.11%).

About Dare Bioscience

DARE stock →

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Vistagen Therapeutics

VTGN stock →

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees

DARE vs VTGN FAQ

Which is bigger, Dare Bioscience or Vistagen Therapeutics?

Dare Bioscience (DARE) is larger, with a market capitalization of $8.01M compared with $7.56M for Vistagen Therapeutics (VTGN).

Which stock has performed better over the past year, DARE or VTGN?

DARE returned -75.75% over the past 12 months, compared with -96.44% for VTGN (price return, excluding dividends). Past performance does not predict future results.

Are Dare Bioscience and Vistagen Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons